[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"non-ischemic-cardiomyopathy\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:non-ischemic-cardiomyopathy":30},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,10,0,[8,52,71,103,123,147,175,207,280,306],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":17,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":20,"targetDuration":23,"studyType":24,"phases":4,"briefSummary":25,"conditions":26,"keywords":37,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":40,"lastUpdatePostDateStruct":41,"startDateStruct":44,"completionDateStruct":46,"leadSponsor":48,"locationsCount":51},"100489526","development-of-circ-technologies-100489526",false,"NCT05654272","Development of CIRC Technologies","Development of Cardiovascular Innovation Research Technologies","CIRC","Inclusion Criteria:\n\n* Age ≥ 18 years of age\n* Provision of written informed consent\n* If not healthy volunteer, must be diagnosed with cardiovascular disease\n\nExclusion Criteria:\n\n* Vulnerable populations will be excluded from this study including Prisoners\n* Other contraindications to CMR imaging to be determined by standard MRI protocols\n* Decisionally impaired (e.g., dementia or cognitive disability)",true,"ALL","18 Years",{"count":21,"type":22},1000,"ESTIMATED","20 Years","OBSERVATIONAL","Cardiovascular disease is the leading cause of death worldwide. Advanced cardiovascular imaging using Magnetic Resonance Imaging (MRI) has proven to be effective in providing gold standard myocardial tissue characterization. Moreover, the intrinsic advantage of MRI's lack of exposure to ionizing radiation is particularly beneficial. At the same time, blood work can be very useful in early detection of certain cardiomyopathy, such as amyloid. However, there is a lack of agreement of on which markers are the most sensitive. This multi-study will allow us the unique opportunity to form a more comprehensive understanding for various cardiovascular diseases.\n\nOur team has developed novel cardiac MRI techniques that leverages endogenous tissue properties to reveal a milieu of deep tissue phenotypes including myocardial inflammation, fibrosis, metabolism, and microstructural defects. Among these phenotypes, myocardial microstructure has proven to be most sensitive to early myocardial tissue damage and is predictive of myocardial regeneration. In this study, the investigators aim to further study the importance of cardiac microstructure revealed by MRI in patient and healthy population and compare this novel technology with conventional clinical biomarkers.",[27,28,29,30,31,32,33,34,35,36],"Cardiovascular Diseases","Heart Failure","Ischemic Heart Disease","Non-ischemic Cardiomyopathy","Valvular Heart Disease","Metabolic Cardiomyopathy","Congenital Heart Disease","Aortic Diseases","Atrial Fibrillation","Ventricular Fibrillation",[38],"MRI","RECRUITING","2026-05-06",{"date":42,"type":43},"2026-05-08","ACTUAL",{"date":45,"type":43},"2022-09-09",{"date":47,"type":22},"2042-09-09",{"name":49,"class":50},"The Cleveland Clinic","OTHER",1,{"id":53,"slug":54,"hasResults":11,"nctId":55,"briefTitle":56,"officialTitle":56,"acronym":4,"eligibilityCriteria":57,"healthyVolunteers":17,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":58,"targetDuration":4,"studyType":24,"phases":4,"briefSummary":59,"conditions":60,"keywords":61,"overallStatus":62,"whyStopped":4,"lastUpdateSubmitDate":63,"lastUpdatePostDateStruct":64,"startDateStruct":66,"completionDateStruct":68,"leadSponsor":70,"locationsCount":4},"100599224","longitudinal-validation-of-circ-technologies-100599224","NCT07081711","Longitudinal Validation of CIRC Technologies","Inclusion Criteria:\n\n* Age ≥ 18 years of age\n* Provision of written informed consent\n\nExclusion Criteria:\n\n* Vulnerable populations will be excluded from this study including Prisoners\n* Other contraindications to CMR imaging to be determined by standard MRI protocols\n* Decisionally impaired (e.g., dementia or cognitive disability)",{"count":21,"type":22},"Cardiovascular disease is the leading cause of death worldwide. Advanced cardiovascular imaging using Magnetic Resonance Imaging (MRI) has proven to be effective in providing gold standard myocardial tissue characterization. Moreover, the intrinsic advantage of MRI's lack of exposure to ionizing radiation is particularly beneficial. At the same time, blood work can be very useful in early detection of certain cardiomyopathy, such as amyloid. However, there is a lack of agreement of on which markers are the most sensitive. This multi-study will allow the unique opportunity to form a more comprehensive understanding for various cardiovascular diseases.\n\nThe study team has developed novel cardiac MRI techniques that leverages endogenous tissue properties to reveal a milieu of deep tissue phenotypes including myocardial inflammation, fibrosis, metabolism, and microstructural defects. Among these phenotypes, myocardial microstructure has proven to be most sensitive to early myocardial tissue damage and is predictive of myocardial regeneration. In this study, the investigators aim to further study the importance of cardiac microstructure revealed by MRI in patient and healthy population and compare this novel technology with conventional clinical biomarkers.",[27,28,29,30,31,32,33,34,35,36],[38],"NOT_YET_RECRUITING","2026-03-19",{"date":65,"type":43},"2026-03-23",{"date":67,"type":22},"2026-04",{"date":69,"type":22},"2037-08",{"name":49,"class":50},{"id":72,"slug":73,"hasResults":11,"nctId":74,"briefTitle":75,"officialTitle":76,"acronym":4,"eligibilityCriteria":77,"healthyVolunteers":11,"sex":18,"minAge":19,"maxAge":78,"enrollmentInfo":79,"targetDuration":4,"studyType":81,"phases":82,"briefSummary":84,"conditions":85,"keywords":88,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":92,"lastUpdatePostDateStruct":93,"startDateStruct":95,"completionDateStruct":97,"leadSponsor":99,"locationsCount":102},"100586795","performance-of-the-cardiac-microcurrent-c-mic-system-with-a-less-invasively-placed-left-ventricular-lead-100586795","NCT06920030","Performance of the Cardiac Microcurrent (C-MIC) System With a Less Invasively Placed Left Ventricular Lead","Pilot Study to Investigate the Performance of the Cardiac Microcurrent (C-MIC) System With a Less Invasively Placed Left Ventricular Lead","Inclusion Criteria Idiopathic Dilated Cardiomyopathy with HFrEF:\n\n1. Patients with idiopathic dilated cardiomyopathy who have systolic left ventricular dysfunction despite adequate therapy of heart failure (NYHA III - IV).\n2. Patients who have a baseline left ventricular ejection fraction of ≥25% and ≤35% assessed by corelab.\n\nInclusion Criteria Non-Ischaemic Cardiomyopathy with HFmrEF:\n\n1. Patients with non-ischemic cardiomyopathy with mildly reduced left ventricular ejection fraction despite adequate therapy of heart failure (NYHA III - IV).\n2. Patients who have a baseline left ventricular ejection fraction of \\>40% and \\\u003C50% assessed by corelab.\n\n   Inclusion Criteria for all Patients:\n3. Patients with symptomatic chronic heart failure for more than 1 year and less than 5 years at screening based on the date of diagnosis.\n4. Female and male patients aged ≥18 years - 75 years.\n5. Patient who understands the nature of the procedure and on-going device therapy. Patient is informed about their participation in a chronic clinical trial and about the intended treatment period of 6 months which is derived by the fact that according to current knowledge microcurrent treatment exceeding 6 months will not have additional favorable effects which means it will not further improve cardiac function. Furthermore, the patient is informed about the possibility of device explantation, informed regarding possible risks and is able to give written informed consent prior to any procedures and is considered willing and able to adhere to the study regimen and to return for all follow-up visits.\n6. Patients receiving appropriate, stable guideline directed medical therapy for heart failure at least for the 3 months prior to screening. Stable is defined as no more than a 50% increase or 50% decrease in dose. If the patient is intolerant of guideline recommended doses of heart failure medication, documented evidence must be available.\n\n   Guideline directed medical therapy includes for:\n\n   • Patients with HFrEF:\n\n   \\- Angiotensin-converting enzyme inhibitor (ACE-I) or\n\n   \\- Angiotensin receptor-neprilysin inhibitor (ARNI)\n\n   \\- Beta-blocker\n\n   \\- Mineralocorticoid receptor antagonist (MRA)\n\n   \\- Dapagliflozin\u002FEmpagliflozin inhibitor (SGLT2i)\n   * Patients with HFmrEF - Diuretics (if symptomatic)\n\n     * Dapagliflozin\u002FEmpagliflozin inhibitor (SGLT2i)\n7. Patients who can perform a non-assisted 6-minute walk test.\n8. Patients must have a body mass index within the range of 20 - 36 kg\u002Fm².\n9. Informed consent in writing obtained from patient.\n\nExclusion Criteria:\n\nPatients who are not likely to experience improvement of their chronic heart failure by the microcurrent therapy, because the causes of the disease cannot be influenced even if the patients fulfill the indication for use of the device or if the therapy with the C-MIC System is not possible or might be associated with unknown risks:\n\n1. Patients who have a potentially correctible cause of heart failure, such as valvular heart disease or congenital heart disease.\n2. Patients with an indication for a CRT system according to current guidelines.\n3. Patients who have been hospitalized for heart failure which required the use of inotropic support within 30 days before screening.\n4. Patients with systolic blood pressure above 150 mmHg and diastolic blood pressure above 90 mmHg despite optimal antihypertensive medical treatment.\n5. Patients with hemoglobin blood level \\\u003C 12 g\u002Fdl in male and \\\u003C 10 g\u002Fdl in female patients.\n6. Patients with primary pulmonary hypertension\n7. Patients who have genetic connective tissue disease (for example Marfan syndrome).\n8. Patients with a prosthetic tricuspid valve.\n9. Patients in whom access for implantation of the leads cannot be obtained (i.e. known venous occlusion, post radiation therapy).\n10. Patient with other features (i.e. thorax deformity) that in the eyes of the investigator make the straightforward placement of the device seem unlikely.\n11. Patients with a pacemaker, an ICD system, a CRT system or with a CCM system.\n12. Current pregnancy or\n13. Breastfeeding\u002Flactating women\n14. Women of childbearing potential, defined as all women physiologically capable of becoming pregnant, unless they are using highly effective methods of contraception (e.g. intrauterine device, oral contraceptives, barrier methods, or other contraception deemed adequate by the investigator) 2 months before and until 1 month after C-MIC therapy.\n\n    Women are considered post-menopausal and not of childbearing potential if they have had 12 months of natural (spontaneous) amenorrhea with an appropriate clinical profile (e.g. age appropriate, history of vasomotor symptoms) or have had surgical bilateral oophorectomy (with or without hysterectomy) or tubal ligation at least 2 months before screening.\n15. Patients whose exercise tolerance is limited by a condition other than heart failure (e.g. chronic obstructive pulmonary disease, peripheral vascular 16.\n\nPatients on immunosuppressive therapy. 17.Patie nts with present malignancy. 18. Patients with an active infection considered by the investigator to be unsafe for the patient's participation in the study.\n\n19\\. Patients with renal dysfunction (i.e., estimated glomerular filtration rate \\\u003C45 mL\u002Fmin \u002F1,73 m²). Use the \"CKD-EPI Creatinine Equation (2021)\" as found on https:\u002F\u002Fwww.kidney.org\u002Fprofessionals\u002Fgfr\\_calculator.\n\n20\\. Patients with history or presence of relevant liver diseases or hepatic dysfunction as indicated by abnormal liver function tests at screening and baseline: ALT (SGPT), AST (SGOT), γ-GT, alkaline, phosphatase and serum bilirubin \\> 2 × upper limit of normal (ULN). Increase of these liver enzymes caused by cardiac disorders in the absence of other possible causes of liver damage are not meant by this.\n\n21\\. Patients with a history of drug or alcohol abuse within the 12 months prior to screening.\n\n22\\. Patients who, in the opinion of the Principal Investigator, are unlikely to comply with the protocol requirements, instructions and trial related restrictions, e.g., uncooperative attitude, inability to return for follow-up visits, psychological illness, and improbability of completing the trial.\n\n23\\. Participation in any study of an investigational device or drug within 90 days prior to planned study.\n\n24\\. Vulnerable Patients (e.g. patients requiring a legal representative, patients kept in detention, any service within the army, and employees of the sponsor or at an investigator site).\n\n25\\. Patients who are not able to avoid the following areas (i.e. due to work):\n\n* Areas with strong magnetic fields\n* Areas with strong external electrical influences\n* Areas with a warning notice \"Access prohibited for pacemaker patients\" or similar.\n* Areas with high temperatures","75 Years",{"count":80,"type":22},22,"INTERVENTIONAL",[83],"NA","Patients with idiopathic dilated cardiomyopathy in heart failure (NYHA class III - IV) with a baseline left ventricular ejection fraction between ≥25% and ≤35%, and patients with non-ischemic cardiomyopathy in heart failure (NYHA class III-IV) with a baseline left ventricular ejection fraction \\>40% and \\\u003C50% despite guideline-directed medical therapy, will receive C-MIC treatment in addition to optimal medical management.\n\nThe device can be implanted without the need for open-heart surgery. Patients are assigned to one of two groups according to the indications under investigation. At the end of the study after 6 months, the C-MIC System will be turned off. The primary endpoint of the study is the absolute change in left ventricular ejection fraction after 6 months of treatment.",[86,87,30],"Idiopathic Cardiomyopathy","Left Ventricular (LV) Systolic Dysfunction",[89,90,91],"dilated cardiomyopathy","heart failure","non-ischemic cardiomyopathy","2026-03-16",{"date":94,"type":43},"2026-03-18",{"date":96,"type":43},"2025-04-09",{"date":98,"type":22},"2027-04",{"name":100,"class":101},"Berlin Heals GmbH","INDUSTRY",4,{"id":104,"slug":105,"hasResults":11,"nctId":106,"briefTitle":107,"officialTitle":108,"acronym":4,"eligibilityCriteria":109,"healthyVolunteers":11,"sex":18,"minAge":110,"maxAge":4,"enrollmentInfo":111,"targetDuration":4,"studyType":24,"phases":4,"briefSummary":112,"conditions":113,"keywords":4,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":114,"lastUpdatePostDateStruct":115,"startDateStruct":117,"completionDateStruct":119,"leadSponsor":121,"locationsCount":51},"100619993","cardiac-magnetic-resonance-for-risk-stratification-in-non-dilated-left-ventricular-cardiomyopathy-100619993","NCT07351838","Cardiac Magnetic Resonance for Risk Stratification in Non-dilated Left Ventricular Cardiomyopathy","Prognosis and Risk Stratification in Non-dilated Left Ventricular Cardiomyopathy : Cardiac MRI Insights for Better Outcomes","Inclusion Criteria:\n\n* age ≥ 16 years;\n* indexed left ventricular end-diastolic volume (LVEDVi) \\\u003C96 mL\u002Fm2 in females and \\\u003C105 mL\u002Fm2 in males at baseline cardiac magnetic resonance (CMR);\n* either left ventricular ejection fraction (LVEF) \\\u003C50% and\u002For non-ischemic left ventricular (LV) scar\u002Ffatty replacement at baseline cardiac magnetic resonance.\n\nExclusion Criteria:\n\n* lacked enhanced CMR images due to contraindications for receiving gadolinium contrast, such as severe renal disease;\n* ischemic heart disease, defined as stenosis of \\>50% in a major epicardial coronary artery underwent coronary computed tomography angiography or coronary angiography, ischemic late gadolinium enhancement (LGE) pattern on CMR indicating prior infarction, or prior coronary revascularization;\n* abnormal loading conditions, defined as moderate to severe valvular heart diseases, congenital heart diseases, uncontrolled hypertension;\n* systemic rheumatologic diseases or sarcoidosis;\n* diagnostic criteria for other cardiomyopathies according to the European Society of Cardiology (ESC) definitions.","16 Years",{"count":21,"type":22},"Non-dilated left ventricular cardiomyopathy (NDLVC), a newly defined cardiomyopathy subtype characterized by non-ischemic myocardial abnormalities without left ventricular dilation, poses challenges in prognosis assessment and risk stratification. This is a retrospective observational study aiming to explore the prognostic value of cardiac magnetic resonance (CMR) findings and identify key risk factors for adverse cardiovascular outcomes in patients with NDLVC.\n\nWe will retrospectively enroll patients diagnosed with NDLVC who underwent CMR examination at the study institution during the predefined study period. CMR parameters, including left ventricular ejection fraction (LVEF), late gadolinium enhancement (LGE) patterns, myocardial strain, and the extent of myocardial fibrosis or fatty replacement, will be extracted and analyzed. The primary endpoint is a composite of major adverse cardiovascular events (MACE), including all-cause mortality, heart transplantation, or left ventricular assist device (LVAD) implantation.\n\nThe study intends to clarify the association between specific CMR features and long-term prognosis in NDLVC patients, thereby establishing a CMR-based risk stratification strategy to guide clinical decision-making and improve patient outcomes. Given the retrospective nature, data will be collected from electronic medical records and CMR databases, with ethical approval obtained prior to study initiation.",[30],"2026-01-19",{"date":116,"type":43},"2026-01-21",{"date":118,"type":43},"2010-01-01",{"date":120,"type":22},"2030-12-30",{"name":122,"class":50},"Chinese Academy of Medical Sciences, Fuwai Hospital",{"id":124,"slug":125,"hasResults":11,"nctId":126,"briefTitle":127,"officialTitle":127,"acronym":128,"eligibilityCriteria":129,"healthyVolunteers":11,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":130,"targetDuration":4,"studyType":81,"phases":132,"briefSummary":133,"conditions":134,"keywords":136,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":138,"lastUpdatePostDateStruct":139,"startDateStruct":141,"completionDateStruct":143,"leadSponsor":145,"locationsCount":51},"100566953","cardiac-radiotherapy-for-heart-failure-100566953","NCT06661876","Cardiac RadiothErapy For hEart faiLure","CREFEL","Inclusion Criteria:\n\n* Patient ≥ 18 years\n* Advanced refractory HF NYHA class II, III or IV\n* Stable HF for the last 6 months with maximal guideline-directed HF therapy\n* Ischemic or dilated cardiomyopathy\n* LVEF at baseline ≤ 35%\n* Ability to give a written informed consent and willingness to return for follow-up\n\nExclusion Criteria:\n\n* Eligible or in consideration for heart transplantation\n* Pregnancy or breastfeeding\n* Previous radiotherapy with cardiac involvement\n* Any condition that is deemed a contraindication in the judgment of the investigators",{"count":131,"type":22},40,[83],"Preliminary data suggests that patients suffering from advanced refractory heart failure (HF) could benefit from single low dose whole heart external beam radiotherapy (EBRT).\n\nObjective: To explore in our center the efficacy of administering a EBRT treatment of 5Gy to the whole heart in patients with advanced and refractory HF. The hypothesis is that 5Gy EBRT to the whole heart can improve the left ventricular ejection fraction (LVEF) of these patients by a clinically relevant 5%.\n\nMain study endpoints: The primary aim is to explore the efficacy of EBRT treatment for advanced refractory HF. Secondary endpoints include an assessment of safety, overall survival, hospital admissions, late toxicity, quality of life and the effect of the treatment on other heart function indicators (left ventricular volumes, NT-proBNP, Troponine, High sensitive CRP).",[28,30,135],"Ischemic Cardiomyopathy",[137,90],"external beam radiotherapy","2025-11-28",{"date":140,"type":43},"2025-12-01",{"date":142,"type":43},"2025-01-01",{"date":144,"type":22},"2027-06-30",{"name":146,"class":50},"Universitaire Ziekenhuizen KU Leuven",{"id":148,"slug":149,"hasResults":11,"nctId":150,"briefTitle":151,"officialTitle":152,"acronym":153,"eligibilityCriteria":154,"healthyVolunteers":11,"sex":18,"minAge":4,"maxAge":4,"enrollmentInfo":155,"targetDuration":157,"studyType":24,"phases":4,"briefSummary":158,"conditions":159,"keywords":160,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":166,"lastUpdatePostDateStruct":167,"startDateStruct":169,"completionDateStruct":171,"leadSponsor":173,"locationsCount":51},"100601463","non-ischemic-cardiomyopathy-registry-biobank-and-imaging-data-repository-100601463","NCT07110818","Non-ischemic Cardiomyopathy Registry, Biobank and Imaging Data Repository","Improving Risk Prediction in Non-ischemic Cardiomyopathy (NICM): An Individualized Multimodality Approach Registry, Biobank and Imaging Data Repository","CaNICM","Inclusion Criteria:\n\n1. LVEF \\\u003C50% and\u002For\n2. LVEF 50-55% with presence of clinically significant late gadolinium enhancement or LV dilatation and being carrier of a non ischemic cardiomyopathy causing gene (Pathogenic or likely pathogenic variant in a Clingen moderate or definite gene)\n\nExclusion Criteria:\n\n* A significant other cause of decreased LVEF such as:\n\n  1. Coronary artery stenosis (Significant lesion on proximal Left anterior descending or Left main, or ≥2 main branches with stenosis. Significant lesion is defined as \\>70% of any artery or \\>50% for the left main artery) or prior history of type 1 myocardial infarction\n  2. Significant congenital heart disease requiring intervention\n  3. Primary valvular disease including moderate to severe aortic stenosis and moderate to severe mitral stenosis, primary severe mitral regurgitation (secondary valvular disease such as mitral regurgitation\u002Ftricuspid regurgitation are not exclusion criteria)\n  4. Other distinct entities: Amyloid heart disease, Chagas, Takotsubo, sarcoidosis, hemochromatosis related cardiomyopathy, HIV related cardiomyopathy are excluded\n  5. Substances\u002Ftherapies induced cardiomyopathy only if they are deemed to be the sole explanation for the cardiomyopathy (at the discretion of the enrolling cardiologist)\n  6. Clear history of burned out hypertrophic cardiomyopathy\n  7. Already had a transplantation at time of first CMR\n  8. Refusal to provide informed consent\n\nAdditional remarks:\n\nPatients aged \\> 70 years of age at first contact with a cardiologist regarding the cardiomyopathy will be limited to maximum 10% of the total enrolled patients by center.\n\nPatients with risk factors (for example, chemotherapy, radiotherapy, alcohol…) for cardiomyopathy are not excluded unless they are deemed to completely account for the phenotype per the treating physician.\n\nThe inclusion is not restricted to adult patients and is planned to be extended to the pediatric population.\n\nAll included patients are recommended to have a CMR performed within 3 years of inclusion.",{"count":156,"type":22},2000,"5 Years","The main goal of CaNICM is to create a central database that includes a biobank and an imaging data repository for patients with non-ischemic cardiomyopathy (NICM), as well as for at-risk family members. This includes people who carry rare genetic variants linked to NICM but do not show symptoms, and first-degree relatives.\n\nThe specific goals of this database and biobank are to:\n\nEnhance investigators' ability to predict the risk of heart rhythm disorders in patients with NICM.\n\nOptimize the timing and approach for screening family members who may carry the disease - determining who to test, when, and how.\n\nFind the best ways to treat family members early to prevent or slow the disease.\n\nFuture Phase - Phase 2 Goal:\n\n4\\. Prospectively evaluate how well this risk prediction model works in real-life clinical settings, and compare it to the current approach, which is often based on a single risk factor.",[30],[161,162,163,164,165],"genetic","echocardiography","cardiac magnetic resonance imaging","biomarker","risk prediction model","2025-08-07",{"date":168,"type":43},"2025-08-13",{"date":170,"type":43},"2024-04-02",{"date":172,"type":22},"2031-04-01",{"name":174,"class":50},"Montreal Heart Institute",{"id":176,"slug":177,"hasResults":11,"nctId":178,"briefTitle":179,"officialTitle":180,"acronym":4,"eligibilityCriteria":181,"healthyVolunteers":11,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":182,"targetDuration":4,"studyType":24,"phases":4,"briefSummary":184,"conditions":185,"keywords":194,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":198,"lastUpdatePostDateStruct":199,"startDateStruct":201,"completionDateStruct":203,"leadSponsor":205,"locationsCount":51},"100562965","cardiovascular-multimodality-imaging-study-100562965","NCT06610019","Cardiovascular Multimodality Imaging Study","Risk Stratification of Ischemic and Non-ischemic Cardiomyopathies in Racial and Ethnic Minority Groups in the Bronx - Cardiovascular Multimodality Imaging Study","Inclusion Criteria:\n\n* Any adult patient (18 years or older) referred for a cardiovascular magnetic resonance (CMR) imaging study in the Montefiore Health System\n\nExclusion Criteria:\n\n* Any patient who does not meet above criteria",{"count":183,"type":22},5000,"Determining the etiology of cardiomyopathy is of high clinical importance for optimal treatment strategy and prediction of prognosis. There is increased risk for cardiovascular disease and higher propensity for cardiovascular related mortality among Black and non-Hispanic White patients. Recently, advanced cardiac imaging has become a vital tool in diagnosis and risk stratification of cardiovascular disease. Very limited data is available on the prevalence and characteristics of different cardiovascular diseases in Hispanic and African American minority groups, therefore, studying different racial and ethnic minority groups in the Bronx population is an exceptionally valuable source to determine the prevalence of cardiomyopathies among minority groups along with study survival in this population. This study aims to determine the etiology of cardiovascular disease in a diverse patient population by utilizing various cardiovascular imaging modalities, with a focus on cardiac magnetic resonance (CMR) imaging and to develop risk stratification models by applying advanced cardiovascular imaging markers.",[30,186,187,188,189,190,191,192,193,28],"Cardiomyopathies","Hypertrophic Cardiomyopathy","Right Ventricular Arrhythmogenic Cardiomyopathy","Cardiac Amyloidosis","Anderson Fabry Disease","Sarcoidosis","Cancer Therapy-related Cardiac Dysfunction","Ventricular Arrythmia",[195,196,197],"Cardiovascular Mortalities","Cardiomagnetic Resonance (CMR) Imaging","Prospective","2025-02-12",{"date":200,"type":43},"2025-02-14",{"date":202,"type":43},"2023-05-01",{"date":204,"type":22},"2031-12",{"name":206,"class":50},"Montefiore Medical Center",{"id":208,"slug":209,"hasResults":11,"nctId":210,"briefTitle":211,"officialTitle":211,"acronym":212,"eligibilityCriteria":213,"healthyVolunteers":11,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":214,"targetDuration":216,"studyType":24,"phases":4,"briefSummary":217,"conditions":218,"keywords":233,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":271,"lastUpdatePostDateStruct":272,"startDateStruct":274,"completionDateStruct":276,"leadSponsor":278,"locationsCount":51},"100562769","multimodal-and-multidisciplinary-approach-to-optimize-diagnostic-prognostic-and-therapeutic-management-of-patients-with-non-ischemic-cardiomyopathies-and-arrhythmogenic-inflammatory-phenotypes-a-multicenter-observational-retrospective-and-prospective-registry-study-100562769","NCT06607471","Multimodal and Multidisciplinary Approach to Optimize Diagnostic, Prognostic, and Therapeutic Management of Patients with Non-ischemic Cardiomyopathies and Arrhythmogenic-inflammatory Phenotypes: a Multicenter, Observational, Retrospective and Prospective Registry Study.","AINICM","Inclusion Criteria:\n\n* Written informed consent. For pediatric patients, consent will be obtained by parents, according to the laws applicable in each of the participating countries.\n* Clinical suspicion of NICM, and\u002For proven diagnosis of any NICM and\u002For genotype consistent with any NICM.\n\nNICMs will include but not limit to: DCM, HCM, RCM, ACM, inflammatory, infiltrative, dysmetabolic, mitochondrial, toxic, neuromuscular, rheumatologic\u002Fautoimmune cardiomyopathies, channelopathies with structural substrates, LVNC, PPCM, AMVP, AFD, athlete's heart, undefined and overlap cardiomyopathies. Additional diseases of the NICM spectrum will be included in parallel with the advance of the current knowledge.\n\nExclusion Criteria:\n\n* Absent informed consent.\n* Proven diagnosis of cardiac disease alternative to NICM.\n* Lack of diagnostic workup suitable for diagnosing NICM, detecting arrhythmias, or detecting M-Infl.\n* For patients retrospectively enrolled: lack of active status of follow-up at the enrolling center.",{"count":215,"type":22},15000,"30 Years","Non-ischemic cardiomyopathies (NICM) represent a heterogeneous group of pathologies characterized by absence of obstructive disease of the epicardial coronary vessels and distinct structural and functional changes of the myocardium. The main identified forms include dilated cardiomyopathy (DCM), hypertrophic cardiomyopathy (HCM), restrictive cardiomyopathy (RCM), and arrhythmogenic cardiomyopathy proper (ACM). More recently, further forms of cardiomyopathy have been described, less common and not uniquely classifiable, including: uncompressed myocardium (LVNC), peripartum cardiomyopathy (PPCM), structural correlates of arrhythmogenic mitral valve prolapse (AMVP), Anderson-Fabry disease (AFD), NICM associated with multi- system neuromuscular or autoimmune diseases, lysosomal diseases, glycogenosis, mitochondrial cytopathies and canal diseases with structural substrates. Finally, there are \"overlap\" forms, characterized by the sharing in the same subject of characteristic aspects of two or more of the above- mentioned diseases; and of the \"undefined\" forms, which to date do not reach the diagnostic criteria for any of the above-mentioned diseases.\n\nTo the best of current knowledge, there are two points discovered in scientific research, namely the description of the arrhythmogenic and \"inflammatory\" phenotypes in a broad sense, which are summarized here with the acronym AINICM. In detail:\n\n1. Arrhythmic manifestations account for the arrhythmogenic component of AINICM, which is not limited to ACM proper. In fact, most of the above diseases have a non-arrhythmic clinical presentation and a prevailing tendency to evolve towards a picture of cardiovascular decompensation. Although sudden arrhythmic death has been described throughout the spectrum of AINICM, early arrhythmic manifestations of such diseases have an unknown prevalence, an uncertain association with different disease genotypes and phenotypes, and still uncertain predictivity of long-term arrhythmic risk. At the same time, optimal diagnostic and therapeutic pathways in arrhythmias associated with AINICM are still being studied.\n2. Myocardial inflammation (M-Infl) accounts for the inflammatory component of AINICM, and has recently been described in association with many AINICM on a genetic basis, including undefined and arrhythmic forms. The data is of high interest not only in the diagnostic, but also in prognostic and therapeutic field. In fact, on the one hand the presence of M-Infl seems to have a physio- pathological role in AINICM; on the other, as already known in myocarditis, the optimal therapeutic paths of arrhythmias may differ in patients with and without M-Infl; in particular, also in the light of the preliminary data available in adult and paediatric AINICM, the inflammatory forms are expected to respond better to immunosuppressive therapy, the arrhythmogenic ones to an ablative therapy with frequent need of implantation of cardiac devices.\n\nBased on the clinical presentation, NICM patients will be divided into arrhythmic (AINICM) and non-arrhythmic patients as study and control groups , respectively. The AINICM group will include presentation with ventricular fibrillation (VF), either sustained or non-sustained ventricular tachycardia (VT; NSVT), frequent premature ventricular complexes (PVC), supraventricular arrhythmias (SVA) and bradyarrhythmias (BA). Clinical presentations other than arrhythmic, including chest pain and heart failure, will define the control group. In parallel, as shown in Figure 1, patients with any evidence of M-Infl will be compared with those showing no signs of M-Infl.",[30,219,220,221,222,223,224,225,226,227,228,229,230,231,232],"Dilated Cardiomyopathy (DCM)","Hypertrophic Cardiomyopathy (HCM)","Restrictive Cardiomyopathy","Arrhythmogenic Cardiomyopathy (AC, ARVD\u002FC)","Left Ventricular Noncompaction","Arrhythmogenic Mitral Valve Prolapse","Peripartum Cardiomyopathy","Anderson-Fabry Disease","Arrhythmic and Inflammatory Non-ischemic Cardiomyopathy","Inflammatory (Non-Arrhythmic) Non-ischemic Cardiomyopathy","Nonischemic Cardiomyopathy Sensu Strictu (Non-inflammatory, Non-arrhythmic)","Major Ventricular Arrhythmias, I.e. Sustained Ventricular Tachycardia, Ventricular Fibrillation, or Appropriate Therapy of Cardiac Device (defibrillators)","Overlapping Phenotype","Undefined Phenotypes",[234,235,236,237,238,239,240,241,242,243,244,245,246,247,248,249,250,251,252,253,254,255,256,257,258,259,260,261,262,263,264,265,266,267,268,269,270],"Arrhythmogenic cardiomyopathy","Adverse event","Anderson-Fabry disease","Arrhythmic and Inflammatory Non-ischemic cardiomyopathy","Arrhythmogenic mitral valve prolapse","Anti tachycardia pacing","Bradiarrhythmias","Cardiac magnetic resonance","Cardiac resynchronization therapy with defibrillator","Computed tomography","Development Safety Update Report","Ethics Committee","Electroanatomical map","Electrocardiogram","Endomyocardial biopsy","Good Clinical Practice","Hypertrophic cardiomyopathy","Implantable cardioverter defibrillator","Informed Consent Form","International Conference on Harmonization","Immunomodulatory therapy","Late gadolinium enhancement","Left ventricular ejection fraction","Left ventricular noncompaction","Last Visit of Last Subject","Myocardial inflammation","Non-ischemic cardiomyopathies","Positron emission tomography","Pacemaker","Peripartum cardiomyopathy","Premature ventricular complexes","Serious Adverse Event","Supraventricular arrhythmias","Ventricular arrhythmias","Ventricular fibrillation","Ventricular tachycardia (sustained)","sudden cardiac death","2024-09-18",{"date":273,"type":43},"2024-09-23",{"date":275,"type":43},"2018-01-30",{"date":277,"type":22},"2035-12-31",{"name":279,"class":50},"Scientific Institute San Raffaele",{"id":281,"slug":282,"hasResults":11,"nctId":283,"briefTitle":284,"officialTitle":285,"acronym":286,"eligibilityCriteria":287,"healthyVolunteers":11,"sex":18,"minAge":288,"maxAge":4,"enrollmentInfo":289,"targetDuration":291,"studyType":24,"phases":4,"briefSummary":292,"conditions":293,"keywords":295,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":297,"lastUpdatePostDateStruct":298,"startDateStruct":300,"completionDateStruct":302,"leadSponsor":304,"locationsCount":51},"100534809","relationship-between-coronary-microvascular-dysfunction-and-improvement-of-left-ventricular-systolic-function-in-patients-with-heart-failure-with-reduced-ejection-fraction-caused-by-non-ischemic-etiology-100534809","NCT06243653","Relationship Between Coronary Microvascular Dysfunction and Improvement of Left Ventricular Systolic Function in Patients With Heart Failure With Reduced Ejection Fraction Caused by Non-ischemic Etiology","The Role of Coronary Microvascular Dysfunction in Improving Left Ventricular Systolic Function Using Registry for Evaluation of Factors associatEd With Heart Failure With Reduced Ejection Fraction Caused by Non-ischemic Etiology (REFERENCE).","HFrEF-CMD","Inclusion Criteria:\n\n* a) Subject must be at least 19 years of age. b) Subject with symptoms or signs of HF (NYHA ≥2 dyspnea) and reduced ejection fraction (LVEF ≤ 40%) c) Subject who clinically need coronary angiography d) Subject who can voluntarily sign informed consent form\n\nExclusion Criteria:\n\n* a) Subject with significant coronary artery stenosis on coronary angiography (diameter stenosis ≥90% or 50-90% with fractional flow reserve \\[FFR\\] ≤0.80) b) Subject scheduled for cardiac replacement therapy (heart transplantation or left ventricular assisted device \\[LVAD\\] implantation) c) HF due to restrictive cardiomyopathy, active myocarditis, or constrictive pericarditis d) Significant valvular heart disease requiring surgery e) Subject who have non-cardiac co-morbid conditions with life expectancy \\\u003C1 year","19 Years",{"count":290,"type":22},200,"1 Year","This study aims to evaluate the incidence of coronary microvascular dysfunction (CMD) and its prognostic implication for the improvement of left ventricular function in patients who have been diagnosed with heart failure with reduced ejection fraction (HFrEF) caused by non-ischemic etiology.",[28,294,30],"Microvascular Angina",[296,91],"coronary microvascular dysfunction","2024-02-05",{"date":299,"type":43},"2024-02-06",{"date":301,"type":43},"2023-08-09",{"date":303,"type":22},"2027-12-31",{"name":305,"class":50},"Samsung Medical Center",{"id":307,"slug":308,"hasResults":11,"nctId":309,"briefTitle":310,"officialTitle":311,"acronym":312,"eligibilityCriteria":313,"healthyVolunteers":11,"sex":18,"minAge":19,"maxAge":314,"enrollmentInfo":315,"targetDuration":317,"studyType":24,"phases":4,"briefSummary":318,"conditions":319,"keywords":327,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":329,"lastUpdatePostDateStruct":330,"startDateStruct":332,"completionDateStruct":334,"leadSponsor":336,"locationsCount":51},"100382854","dzhk-torch-plus-is-a-registry-for-patients-with-cardiomyopathies-and-serves-as-source-for-cardiovascular-research-studies-100382854","NCT04265040","DZHK TORCH-Plus is a Registry for Patients With Cardiomyopathies and Serves as Source for Cardiovascular Research Studies","TranslatiOnal Registry for CardiomyopatHies (TORCH) - Plus as Part of the German Centre for Cardiovascular Research (DZHK)","TORCH-Plus","Inclusion Criteria:\n\n* Non-ischemic structural cardiomyopathies\n* Age ≥ 18 or ≤ 80 years\n* The patient is able to understand the declaration of consent and to sign it dated\n* At least one of the following diagnoses depending on the specific TORCH-\n\nPlus inclusion \u002F exclusion - SOP:\n\nDilated Cardiomyopathy (DCM)\n\n* family \u002F genetic\n* inflammatory \u002F persistent myocarditis\n* idiopathic (after exclusion secondary cause)\n* left sided systolic dysfunction (EF ≤ 45%)\n\nLeft ventricular hypertrophy\n\n* sarcomere hypertrophic cardiomoypathia (HCM, HOCM)\n* amyloid (AL: light chains, TTR: transthyretin, wild type)\n\nLeft ventricular non-compaction cardiomyopathy (LVNC)\n\nArrhythmogenic right ventricular cardiomyopathy (ARVC \u002F D)\n\nExclusion Criteria:\n\nThe following exclusion criteria have been defined and must be taken from the TORCH-Plus specific inclusion \u002F exclusion - SOP in detail:\n\n* Age: \\\u003C18 years or\\> 80 years\n* Patient has other (cardiac) previous illnesses:\n\n  * uncontrollable arterial hypertension\n  * primary pulmonary arterial hypertension\n  * radiation therapy in the chest area\n  * addiction (drug or alcohol abuse)\n  * life expectancy \\\u003C1 year due to non-cardiological pre-existing conditions\n  * significant heart valve disease\n  * ischemic diseases and severe congenital heart diseases (including VSD, Fallot tetralogy, Ebstein anomaly)\n  * chemotoxic cardiomyopathy\n  * condition after myocarditis\n  * combination of several traditional risk factors (e.g. hypertension and diabetes mellitus)\n  * advanced chronic non-cardiac disease (e.g. chronic hepatitis or HIV)\n  * Tachymyopathy","80 Years",{"count":316,"type":22},2040,"4 Years","The DZHK TranslatiOnal Registry for CardiomyopatHies (DZHK TORCH) represents a unique resource of clinical data and high quality biological samples to enable innovative clinical and molecular studies on cardiomyopathies (CMP). As a multi-center German cardiomyopathy registry, TORCH has been prospectively admitting patients since December 2014. 2,300 patients were recruited as planned. Taken together, patient data showed that the prevalence of these diseases is much higher in men than in women, atrial fibrillation is common in all forms of CMPs as well as rare forms of disease indicate a higher risk and higher morbidity.\n\nThis DZHK TORCH register is now to be expanded with a second phase (DZHK TORCH-Plus). The second phase DZHK TORCH-Plus consists of 4 main modules: 1. \"Clinical phenotyping, follow-up \\& biosampling\" 2. \"Genomics\", 3. \"Inflammation\" and 4. \"Biomarker\". The central aims are 1) to significantly increase the number of probands (n = 4340) in order to better address the different types of CMPs, especially patients with rare CMP forms such as LVNC and ARVC or with probably molecularly explainable cardiomyopathies (familial DCM), 2) to prolong the longitudinal with a further follow-up to achieve sufficient events and thereby derive clinical recommendations for risk assessment, 3) to increase the number of probands with state-of-the-art phenotyping, 4) to pinpoint the effect of myocardial inflammation, fibrosis, gender and to determine or predict genotypes based for outcome, 5) to validate novel biomarkers developed in other DZHK studies, and 6) to foster active cooperation with international CMP registries and partners from industry.",[30,320,321,322,323,324,325,326],"DCM - Dilated Cardiomyopathy","HCM - Hypertrophic Cardiomyopathy","HOCM - Hypertrophic Obstructive Cardiomyopathy","Arrhythmogenic Right Ventricular Cardiomyopathy","Left Ventricular Noncompaction Cardiomyopathy","Amyloidosis","Inflammatory Cardiomyopathy",[328],"Cardiomyopathies, registry, data, biomaterial, genetics","2023-11-29",{"date":331,"type":43},"2023-11-30",{"date":333,"type":43},"2020-08-18",{"date":335,"type":22},"2027-12",{"name":337,"class":50},"University Hospital Heidelberg"]